Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + disease + 0.23  Related to the article below (Last Update: 8/5/2008)

Geron Corporation Reports 2008 Second Quarter Financial Results ...
MarketWatch - Jul 30, 2008
Net loss applicable to common stockholders for the first six months of 2008 was $27.2 million, or $(0.35) per share, compared to $16.5 million or $(0.23) ...GERN
* US, European stocks fall on oil surge, economy jitters
guardian.co.uk, UK - Aug 1, 2008
Two new brain disease cases were detected in patients taking Tysabri, a multiple sclerosis drug jointly manufactured with its Irish partner Elan, ...
Richard Aster Jr Buys Cooper Industries Ltd., Covidien Ltd ...
GuruFocus.com, TX -
CBRL Group Inc. has a market cap of $540.66 million; its shares were traded at around $24.41 with a P/E ratio of 8.03 and P/S ratio of 0.23. ...CEPH - AEO - SCUR
Patients With Colon Cancer Who Have A Family History Of Colorectal ...
Medical News Today (press release), UK - Jul 30, 2008
Studies have shown that a history of colorectal cancer in a first-degree relative nearly doubles the risk of developing the disease. ...
Illumina Reports Financial Results for Second Quarter 2008
FOXBusiness - Jul 23, 2008
Illumina's technology will be used as part of the project to identify the genetic variants responsible for disease and human diversity. ...ILMN
pSivida Quarterly Highlights
Business Wire (press release), CA - Jul 31, 2008
A total of 37 subjects were enrolled in this trial, 20 patients on the low dose (an approximate 0.23mcg per day dose) of Medidur and 17 patients on the high ...PSDV - ASX:PVA - ALIM
Helicobacter pylori: Friend or Foe?
Medscape (subscription) - Jul 9, 2008
Although gastric atrophy was uncommon, there was an inverse relationship with Barrett's esophagus, nonjunctional esophageal adenocarcinoma, and GERD (0.23 ...
MIV Provides Update on Its Next-Generation, Ultra-Thin Protea TM ...
Business Wire (press release), CA - Jul 16, 2008
We are optimistic that the Protea will prove to be an important part of the physician?s armamentarium in the treatment of heart disease. ...OTC:MIVI
Vitamin C Intake Linked to Lower Risk for Type 2 Diabetes
Medscape (subscription) - Jul 29, 2008
The OR for diabetes of those in the highest quintile of plasma vitamin C was 0.23 in the unadjusted model; in a model adjusted for BMI and waist ...
Effect of Simvastatin on Cognitive Functioning in Children With ...
Journal of American Medical Association (subscription), IL - Jul 15, 2008
For instance, for the Rey CFT (recall) (β = 0.10, SE = 0.23), we can reject a change larger than 0.56, and for the cancellation test (speed) (β = ?0.19, ...
Source: Google News

… therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD … -
EJ Irvine - J Clin Gastroenterol, 1995 - ncbi.nlm.nih.gov
... disease as measured by a new disease activity index. ... and treatment was prescribed
for the perianal disease. ... and HBDAI correlated poorly with PDAI (R < 0.23). ...

New disease resistance genes in soybean against Pseudomonas syringae pv glycinea: evidence that one … -
NT Keen, RI Buzzell - TAG Theoretical and Applied Genetics, 1991 - Springer
... New disease resistance genes in soybean against ... contained a putative disease resistance
gene complementary to avrD. ... 79 68 74 72 Chi-square" 0.66 0.23 0.27 0.02 ...

Developing the Vascular Quality of Life Questionnaire: A new disease-specific quality of life … -
MBF Morgan, T Crayford, B Murrin, SCA Fraser - Journal of Vascular Surgery, 2001 - Elsevier
... the patients at this stage, no new items emerged ... Health perception ? 0.38? 0.27 0.28
0.39 0.23 ... Another disease-specific QOL questionnaire for patients with ...

… platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease -
MJ Caslake, CJ Packard, KE Suckling, SD Holmes, P … - Atherosclerosis, 2000 - Elsevier
... The ability of a parameter to predict disease was tested by ... content, Lp-PLA 2 mass
using the new two-site ... r=0.59, P<0.001), triglyceride (r=0.23, P<0.01). ...

Predictors of New-Onset Kidney Disease in a Community-Based Population -
CS Fox, MG Larson, EP Leip, B Culleton, PWF Wilson … - JAMA, 2004 - Am Med Assoc
... the Cleveland Clinic Laboratory, requiring a correction factor of 0.23 mg/dL ... are
important risk factors for the development of new-onset kidney disease. ...

Co-enzyme Q10: a new drug for cardiovascular disease -
S Greenberg, WH Frishman - The Journal of Clinical Pharmacology, 1990 - jcp.sagepub.com
... Pharmacology The Journal of Clinical 1990; 30; 596 J. Clin. Pharmacol. S Greenberg
and WH Frishman Co-enzyme Q10: a new drug for cardiovascular disease ...

Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia … -
LA CARLSON - European Journal of Clinical Investigation, 1982 - Blackwell Synergy
... signs [S]. We here describe a further, new familial disease ... 0 IV 4.01 4.43 2.02 3.21
0.63 0.23 0.08 2.91 ... triglycer- ides which for fish eye disease cases were ...

The Relation between Funding by the National Institutes of Health and the Burden of Disease -
CP Gross, GF Anderson, NR Powe - New England Journal of Medicine, 1999 - content.nejm.org
... condition or disease (P=0.82, P=0.23, and P ... Evaluating the Burden of Disease and
Spending the Research ... The New England Journal of Medicine is owned, published ...

The Impact of Nocturnal Symptoms Associated With Gastroesophageal Reflux Disease on Health-Related … -
C Farup, L Kleinman, S Sloan, D Ganoczy, E Chee, C … - Archives of Internal Medicine, 2001 - Am Med Assoc
... in this window] [in a new window]. ... Scores for Nocturnal Gastroesophageal Reflux Disease
(GERD), Hypertension ... health (r = -0.24), pain (r = -0.23), and general ...

A spatially aggregated disease/host model for bovine Tb in New Zealand possum populations. -
ND Barlow - Journal of Applied Ecology, 1991 - JSTOR
... 0.031 0.81 2.04 1.15 4.0 10.0 1.0 0.23 1.0 0.041 ... Ministry of Agriculture and Fisheries,
Wellington, New Zealand. ... an outbreak of foot and mouth disease in feral ...

Source: Google Scholar

Certolizumab Pego ; An Effective New Therapy For Patients With Crohn's Disease
Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. These findings were published in today's issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohn's disease.

Crohn's disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. Symptoms include abdominal pain, fever, nausea, vomiting, weight loss and diarrhea. Crohn's disease has no known medical cure. Currently approved therapies that also block tumor necrosis factor include intravenous infusions of infliximab or subcutaneous injections of adalimumab.
"Many patients with Crohn's disease who receive repeated administration of infliximab or adalimumab will eventually stop responding to the therapy," says William Sandborn, M.D., a study author and gastroenterologist at Mayo Clinic. "Therefore, it is important to have a variety of options in this drug class to help patients avoid Crohn's disease symptoms over longer periods of time."

According to Dr. Sandborn, the dosing regimen for certolizumab pegol is more patient-friendly than infliximab or adalimumab, with less frequent subcutaneous injections that can be self-administered.

The first study, led by Dr. Sandborn, set out to determine if certolizumab pegol was effective in easing the symptoms of patients with active Crohn's disease. The study involved 662 adult patients with moderate to severe Crohn's disease, and represents a unique trial design in Crohn's disease. This is the first double-blind, placebo-controlled trial in which a drug that blocks tumor necrosis factor has been evaluated beyond 12 weeks in the treatment of Crohn's disease. Researchers found that 35 percent of patients who received certolizumab pegol achieved an improvement in their clinical symptoms after six weeks, while 27 percent of patients who received a placebo experienced improved symptoms in the same period. Likewise, after six months, 37 percent of patients who received certolizumab pegol achieved an improvement in their clinical symptoms, compared to 27 percent of patients who received a placebo.

The second study set out to determine if certolizumab pegol was effective as a long-term maintenance therapy for patients with Crohn's disease. It involved 668 patients, of whom 428 (64 percent), responded, or achieved an improvement in their clinical symptoms, after taking certolizumab pegol for six weeks. The response was maintained for six months in 63 percent of patients receiving certolizumab pegol, while 36 percent of patients who received a placebo from week six to six months experienced improved symptoms in that period. Additionally, clinical remission from symptoms was achieved in 48 percent of patients in the certolizumab pegol group, compared to 29 percent of those in the placebo group.

Certolizumab pegol is not yet approved by the Food and Drug Administration (FDA). One side effect of certolizumab pegol that was observed during the studies, and is seen in other drugs that block tumor necrosis factor, was a small increase in the risk for serious infection, including one case of pulmonary tuberculosis. However, injection-site reactions were very low and patients experienced low rates of antinuclear antibodies, which can occasionally cause lupus-like symptoms when elevated.
"Approximately 25 percent of the patients in these studies had previously been treated with infliximab therapy and had lost response," says Dr. Sandborn. "These studies show that certolizumab pegol could be a new option to treat patients with Crohn's disease, both those who have never been treated before, and those who have lost response to other therapies. Upon FDA approval, the use of certolizumab pegol could significantly improve quality of life for many patients with Crohn's disease."

Mayo Clinic is participating in ongoing clinical trials to examine the safety and effectiveness of using certolizumab pegol to treat Crohn's disease symptoms beyond six months. Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat approximately 2,000 patients who have Crohn's disease. For more information on the treatment of Crohn's disease at Mayo Clinic, visit http://www.mayoclinic.org/crohns/.

This research was funded by UCB Pharma, Inc. Mayo Clinic receives consulting fees from UCB Pharma, Inc. for work performed by Dr. Sandborn. Certolizumab pegol is a product of UCB Pharma, Inc.

Source: Elizabeth Rice
Mayo Clinic
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.